A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

Not Applicable

Recruiting

• Conditions: Attention-Deficit Hyperactivity Disorder(ADHD)
• Interventions: Drug: EB-1020 (Centanafadine) low dose; Drug: EB-1020 (Centanafadine) high dose; Drug: Placebo

• Registration Number: NCT07086313
• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-17
• Study First Submitted QC: 2025-07-17
• Last Update Submitted: 2025-07-17
• Study First Posted: 2025-07-25
• Last Update Posted: 2025-07-25
• Study Start: 2025-08-01
• Primary Completion: 2027-08
• Study Completion: 2027-08-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 315

Inclusion Criteria

• Participants with a primary diagnosis of ADHD based on DSM-5 diagnostic criteria, differentiated from other mental disorders using the MINI-KID, excluding other specified ADHD or unspecified ADHD.
• Participants with a symptom total raw score of>=28 (if not receiving any pharmacological treatment for ADHD) or>=22 (if receiving pharmacological treatment for ADHD) on the ADHD Rating Scale Version 5 (ADHD-RS-5) at screening.
• Participants with a symptom total raw score of>=28 on the ADHD-RS-5 at baseline.
• Participants with a score of 4 or higher on the Clinical Global Impression Severity - ADHD (CGI-S-ADHD) at baseline.

Exclusion Criteria

• Participants who have a positive pregnancy test result at baseline.

• Participants determined to have the following diseases based on an interview using the MINI-KID.

  • Tourette's disorder
  • Panic disorder
  • Conduct disorder
  • Psychotic disorder
  • Post-traumatic stress disorder
  • Bipolar disorder

• Participants with a generalized anxiety disorder requiring pharmacotherapy, based on the DSM-5 diagnostic criteria.

• Participants with an autism spectrum disorder based on the DSM-5 diagnostic criteria.

• Participants with a personality disorder, oppositional defiant disorder, or obsessive-compulsive disorder that is the primary focus of treatment, based on the DSM-5 diagnostic criteria.

• Participants with a diagnosis of major depressive disorder (MDD), based on the DSM-5 diagnostic criteria who currently have a major depressive episode, or who have required treatment for MDD within the past 3 months prior to screening.

Also, participants who, in the judgment of the investigator or subinvestigator, may have a worsening of MDD during the trial or may require treatment during the trial period.

• Participants who have a diagnosis of intellectual disability with an intelligence quotient (IQ) score less than 70.

• Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence.

  • Active suicidal ideation as evidenced by an answer of "yes" on Questions 4 or 5 (over the last 6 months) on the section of suicidal ideation or a history of suicidal behavior (over the last 6 months) on the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening.

• Participants with a diagnosis of substance use disorder.

  • Platelets <= 130,000/mm3
  • Hemoglobin <= 11.2 g/dL
  • Neutrophils, absolute <= 1000/mm3
  • AST > 2 x ULN
  • ALT > 2 x ULN
  • eGFR < 45 mL/min/1.73 m2, calculated by the CKiD U25 equation
  • CPK >= 2 x ULN (except for the cases that the medical monitor determined that participant's inclusion is possible based on the discussion about the participant's condition with the investigator or subinvestigator)
  • Abnormal values for both free T4 and TSH

• Participants who cannot agree to discontinuation of prohibited concomitant medication, such as ADHD medication or antidepressants.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EB-1020(QD XR capsules) low dose	EB-1020 (Centanafadine) low dose	-
EB-1020(QD XR capsules) high dose	EB-1020 (Centanafadine) high dose	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Change from baseline in ADHD-RS-5 symptom total raw score at Week 6.	Baseline, Weeks 6	The ADHD-RS-5 is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (never to rarely/no problem) to 3 (very often/severe problem). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Negative change from Baseline indicates improvement. Mixed-effect model repeated measure (MMRM) was used for analysis.

Trial Locations

Locations (1)

Hokkaido University Hospital; 🇯🇵 Sapporo, Japan